•  

    Education and Experience

    I am excited to begin my 5th year as a chemistry teacher at Verona High School.  I have taught both honors and college preparatory chemistry each year at Verona High School.  There is simply nothing like seeing a student realize their full potential.  
     

    I received my bachelor’s degree in chemistry from the Massachusetts Institute of Technology in 1999, doing undergraduate research for 2.5 years under the direction of Rick Danheiser.  I then continued my education at Yale University where I received my master’s degree in chemistry in 2001, doing research for John Wood.

    After graduate school, I worked from 2001-2013 at Roche Pharmaceuticals as a synthetic medicinal chemist designing and synthesizing novel differentiated medicines to treat diseases including cancer and type 2 diabetes.   One of the compounds that I worked on is currently in clinical trails.  During these years, I became an inventor on 15 patents and 6 additional publications (see below).

    I completed a 1.5 year teacher certification course through William Paterson University in December of 2013, completing my student teaching at Summit High School.  I then held a long-term substitute teaching position at Parsippany High School from January through May of 2014 where I was responsible for two section of CP chemistry and two sections of AP chemistry. 

     

    Honors and Awards 

     

    Inducted into Kappa Delta Pi - Alpha Zeta chapter (International Honor Society in Education) at William Paterson University

     

    Inducted into Phi Beta Kappa (the nation’s oldest honor society) at M.I.T.

     

    Received the Merck Index award for academic excellence at M.I.T.  

     

    Inducted into Alpha Chi Sigma (Professional Chemistry Fraternity) at M.I.T  

    President of M.I.T.’s Alpha Zeta chapter 1998-1999

     

    Publications 

     

     

    Discovery of camphor-derived pyrazolones as 11β-hydroxysteroid dehydrogenase type 1 inhibitors.

    Gillespie, P.; Pietranico-Cole, S.; Myers, M.; Bilotta, J.A.; Conde-Knape, K.; Fotouhi, N.; Goodnow, R.A., Jr.; Guertin, K.R.; Hamilton, M.M.; Haynes, N.-E.; Liu, B.; Qi, L.; Ren, Y.; Scott, N.R.; So, S.-S.; Spence, C.; Taub, R.; Thakkar, K.; Tilley, J.W.; Zwingelstein, C. 

    Bioorg. Med. Chem. Lett., 2014, 24, 2707-2711. 

     

    Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a highly selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia.

    Kelly, M.J.; Pietranico-Cole, S.; Larigan, J.D.; Haynes, N.-E.; Reynolds, C.H.; Scott, N.; Vermeulen, J.; Dvorozniak, M.; Conde-Knape, K.; Huang, K.-S.; So, S.-S.; Thakkar, K.; Qian, Y.; Banner, B.; Mennona, F.; Danzi, S.; Klein, I.; Taub, R.; Tilley, J. 

    J. Med. Chem., 2014, 57, 3912-3923. 

     

    Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase.

    Zak, M.; Haynes, N.-E.; Hermann, J.C.; Kim, K.; Scott, N.R.; Yi, L.

    WO 2013182580 (20130605).   

     

    Preparation of pyrrolopyrimidones and pyrrolopyridones as tankyrase inhibitors.

    Zak, M.; Haynes, N.-E.; Hermann, J.C.; Kim, K.; Scott, N.R.; Yi, L.

    WO 2013182580 (20130605). 

     

    Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase.

    Feng, J.; Haynes, N.-E.; Hermann, J.C.; Kim, K.; Liu, J.-J.; Scott, N.R.; Yi, L.; Zak, M.; Zhao, G.

    WO 2013182546 (20130604).   

     

    Preparation of pyrazolopyrimidones and pyrazolopyridones as tankyrase inhibitors.

    Feng, J.; Haynes, N.-E.; Hermann, J.C.; Kim, K.; Liu, J.-J.; Scott, N.R.; Yi, L.; Zak, M.; Zhao, G.

    WO 2013182546 (20130604). 

     

    Identification of RO4597014, a Glucokinase Activator Studied in the Clinic for the Treatment of Type 2 Diabetes

    Yimin Qian, Wendy L. Corbett, Steven J. Berthel, Duk Soon Choi, Mark T. Dvorozniak, Wanping Geng, Paul Gillespie, Kevin R. Guertin, Nancy-Ellen Haynes, Robert F. Kester, Francis A. Mennona, David Moore, Jagdish Racha, Roumen Radinov, Ramakanth Sarabu, Nathan R. Scott, Joseph Grimsby, and Navita L. Mallalieu

    ACS Med. Chem. Lett., 2013, 4 (4), pp 414–418.

     

     

    Metal Impurities Cause False Positives in High-Throughput Screening Campaigns

    Hermann, J.C.; Chen, Y.; Wartchow, C.; Menke, J.; Gao, L.; Gleason, S.K.; Haynes, N.-E.; Scott, N.; Petersen, A.; Gabriel, S.; Vu, B.; Goerge, K.M.; Narayanan, A.; Li. S.H.; Qian, H.; Beatini, N.; Niu, L.; Gan, Q.-F. 

    ACS Med. Chem. Lett. 2013, 4, 197-200.

     

     

    Preparation of N-substituted 2-(benzenesulfinyl)acetamides as PARP inhibitors

    Haynes, N.-E.; Huby, N.J.S.; Scott, N.R. 

    WO 2013030205.

     

    Discovery and development of MGL-3196, a liver-directed thyroid hormone beta agonist for the treatment of hypercholesterolemia/dyslipidemia and hypertriglyceridemia

    Martha J. Kelly, J. Douglas Larigan, Sherrie Pietranico-Cole, Joseph Grimsby, Jefferson Tilley, Nancy-Ellen Haynes, Nathan Scott, John Vermeulen, Mark Dvorozniak, Karin Conde-Knape, Kuo-Sen Huang, Lianhe Shu, Ping Wang,

    Angelique Braen, Anjula Pamidimukkala, Sung-Sau So, Kshitij Thakkar, Yimin Qian, Bruce Banner, Frank Mennona, Irwin Klein, Edward Chiang, Rebecca Taub. 

    245th American Chemical Society National Meeting, 7-11 Apr 2013,

    New Orleans, LA, USA.  Abstract No. MEDI-280.

     

    Preparation of adamantane derivatives for treatment of JNKs-mediated disorders.

    Cheung, A.W.-H.; Guertin, K.R.; Haynes, N.-E.; Mertz, E.; Qi, L.; Qian, Y.; Scott, N.R.

    WO 2012136684 (20120404). 

     

    Identification of an Adamantyl Azaquinolone JNK Selective Inhibitor

    Nancy-Ellen Haynes, Nathan R. Scott, Li C. Chen, Cheryl A. Janson, Jia Kui Li, Christine M. Lukacs, Aruna Railkar, Effie Tozzo, Toni Whittard, Nicholas F. Brown, and Adrian Wai-Hing Cheung

    ACS Med. Chem. Lett., 2012, 3 (9), pp 764–768. 

     

     

    N-(Pyrazolylcarbamoylalkyl)pyridone derivatives as glucokinase activators and their preparation and use for the treatment of metabolic diseases

    Haynes, N.-E.; Scott, N.R.; Tilley, J.W. 

    WO 2011009845 A1.

     

     

    Pyrrolidinone as glucokinase activators and their preparation, pharmaceutical compositions and use in the treatment of metabolic disorders

    Berthel, S.J.; Brinkman, J.A.; Hayden, S.; Haynes, N.-E.; Kester, R.F.; McDermott, L.A.; Qian, Y.; Sarabu, R.;

    Scott, N.R.; Tilley, J.W. 

    WO 2009127546 (US 7741327 (22 Jun 2010)).

     

     

    Pyridazinones as glucokinase activators and their preparation, pharmaceutical compositions and use in the treatment of metabolic disorders

    Berthel, S.J.; Haynes, N.-E.; Kester, R.F.; McDermott, L.A.; Qian, Y.; Sarabu, R.; Scott, N.R.; Tilley, J.W. 

    WO 2009127544 A1.

     

     

    Preparation of pyridazinones as thyroid hormone prodrugs

    Haynes, N.-E.; Scott, N.R.; Tilley, J.W. 

    WO 2009037172 (US 8076334 (13 Dec 2011)).

     

     

    Preparation of pyrazole-4-carboxamide derivatives as 11-beta-hydroxysteroid dehydrogenase form I (11-beta-

     

    HSD1) inhibitors

    Anderson, K.W.; Fotouhi, N.; Gillespie, P.; Goodnow, R.A., Jr.; Guertin, K.R.; Haynes, N.-E.; Myers, M.P.; Pietranico-Cole, S.L.; Qi, L.; Rossman, P.L.; Scott, N.R.; Thakkar, K.C.; Tilley, J.W.; Zhang, Q.   

    WO 2007107470 (US 7728029 (1 Jun 2010)).

     

     

    Preparation of pyrazolones as inhibitors of 11ß-hydroxysteroid dehydrogenase

    Banner, B.L.; Bilotta, J.A.; Fotouhi, N.; Gillespie, P.; Goodnow, R.A.; Hamilton, M.M.; Haynes, N.-E.; Kowalczyk, A.; Mayweg, A.; Myers, M.P.; Pietranico-Cole, S.L.; Scott, N.R.; Thakkar, K.C; Tilley, J.W.  

    US 20070049632 (US 7622492 (24 Nov 2009)).

     

    Preparation of pyridazinone derivatives as thyroid hormone receptor agonists for treating metabolic disorders and other diseases

    Haynes, N.-E.; Kertesz, D.J.; Pietranico-Cole, S.L.; Qian, Y.; Scott, N.R.; So, S.-S.; Thakkar, K.C.; Tilley, J.W.  

    WO 2007009913 (US 7452882 (18 Nov 2008), US 7807674 (5 Oct 2010)).

     

     

    Preparation of pyrazines and related compounds as glucokinase activators for the treatment of type II diabetes

    Chen, S.; Corbett, W.L.; Guertin, K.R.; Haynes, N.-E.; Kester, R.F.; Mennona, F.A.; Mischke, S.G.; Qian, Y.; Sarabu, R.; Scott, N.R.; Thakkar, K.C.  

    WO 2004052869 (US 7132425 (7 Nov 2006)).

     

Last Modified on June 6, 2018